**Question:** The following anti-TB drug should not be given to an AIDS patient:

A. Isoniazid
B. Ethambutol
C. Pyrazinamide
D. Rifampicin

**Core Concept:** Anti-tuberculosis (anti-TB) drugs are used to treat Mycobacterium tuberculosis infections. AIDS (Acquired Immunodeficiency Syndrome) patients have compromised immune systems, which predisposes them to severe side effects and drug interactions.

**Why the Correct Answer is Right:** In the context of AIDS patients, we should avoid administering Rifampicin (D) due to several reasons:

1. **Rifampicin Interactions:** Rifampicin is a potent inducer of drug-metabolizing enzymes, particularly cytochrome P450 enzymes. This can lead to decreased plasma levels of many medications, including antiretroviral drugs (used in AIDS treatment) and thus, rendering them less effective, potentially compromising the patient's health.

2. **Rifampicin-induced Hepatotoxicity:** Rifampicin can cause hepatotoxicity (liver damage) in AIDS patients due to the increased risk of drug-induced liver injury in immunocompromised individuals.

**Why Each Wrong Option is Incorrect:**

3. **Neither Inducer nor Inhibitor:** Options A (Isoniazid) and C (Pyrazinamide) are neither potent inducers nor inhibitors of drug-metabolizing enzymes, making them less concerning in the context of AIDS patients.

4. **Safer Drugs in AIDS Patients:** Option B (Ethambutol) is a safer choice for AIDS patients as it has fewer interactions with other medications and is less likely to cause hepatotoxicity.

**Clinical Pearl:** In treating tuberculosis (TB) in patients with AIDS, it is crucial to consider the potential interactions and side effects of anti-TB drugs. Always consult with a physician when treating TB in immunocompromised patients like those with AIDS, as a tailored treatment plan and close monitoring is essential to ensure the best outcome for the patient.